Warren Buffett Buys $60 Million Worth of Teva in the Dip
Berkshire Hathaway also massively invested more in Goldman Sachs and Apple
Teva Pharmaceutical
Teva Shares Tumble After Company Disappoints Markets
The pharmaceutical company is in a $28.4 billion debt. Analysts says the company still lacks growth drivers
Teva Surprises With Better-than-expected First Quarter
Trouble drugmaker offers rosier outlook for rest of year, despite delay in approval for key migraine treatment
The Ticker: Buffett Says Decision to Buy Teva Stake Was Taken by Deputies
Elsztain enlists unions to help block sale of Clal Insurance ■ Medical-marijuana shares get lift as lawmakers express support for exports ■ Shares end mixed as bank stage powerful rally
Opinion Israel Needs to Find a Better Financial Role Model Than America
U.S. President Trump’s obsession with the stock market as a gauge of his success augurs ill, and Israel needs to rethink its own strategy
Business in Brief: Teva Unfazed as U.S. Approves Second Generic Rival for Copaxone
Gilat finally swings to profit ■ Leumi turns bearish on Leviathan ■ Stocks end mixed
Four Top Execs Cost Teva $31 Million in 2017, Even as It Posted Huge Losses
Nearly half went to three managers leading company during failed Actavis acquisition
The Ticker: Shares Slump on Teva and Wall Street
Police raid Shapir offices, question four ■ Fattal Hotels cuts valuation on IPO by 25% ■ Starwood Retail files to sell a billion shekels in bonds in Tel Aviv
Teva Reports Massive $11.6 Billion Loss, Predicts Weak 2018
Shares tumble amid concerns that turnaround with the company's new CEO may take longer than expected
Teva Files to Raise $5 Billion in Debt Issue
Business in Brief | Bezeq to shuffle board; Noble to cut stake in Tamar gas field; Dorit Wertheim sells Aloni Hetz stake to brother; Biomed and insurance stocks fall